
SynBioBeta Speaker
Avantika Lal
Genentech
Principal ML Scientist II
I am a researcher working at the cross-section of machine learning and genomics. The goal of my research is to use deep learning models to understand the regulatory syntax of the human genome, reveal the molecular mechanisms underlying complex diseases, and design new therapeutics.
Sessions Featuring
Avantika
This Year
•
-
AIxBIO
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
Featuring

Andrei Georgescu
Vivodyne
CEO

Johnny Yu
Tahoe Therapeutics
CSO & Co-founder

Avantika Lal
Genentech
Principal ML Scientist II
Building DNA foundation models that design regulatory sequences.

Daniel Georgiev
Sampling Human
CEO & Co-founder

Krish Ramadurai
AIX Ventures
Partner
TechBio investor backing AI-designed drugs and breakthroughs.
•
-
AIxBIO
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
Featuring

Andrei Georgescu
Vivodyne
CEO

Johnny Yu
Tahoe Therapeutics
CSO & Co-founder

Avantika Lal
Genentech
Principal ML Scientist II
Building DNA foundation models that design regulatory sequences.

Daniel Georgiev
Sampling Human
CEO & Co-founder

Krish Ramadurai
AIX Ventures
Partner
TechBio investor backing AI-designed drugs and breakthroughs.




































